28.94
-1.2(-3.98%)
Currency In USD
| Previous Close | 30.14 |
| Open | 29.73 |
| Day High | 29.88 |
| Day Low | 28.89 |
| 52-Week High | 35.79 |
| 52-Week Low | 19.25 |
| Volume | 622,858 |
| Average Volume | 963,049 |
| Market Cap | 1.93B |
| PE | -6.78 |
| EPS | -4.27 |
| Moving Average 50 Days | 32.23 |
| Moving Average 200 Days | 27.51 |
| Change | -1.2 |
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
GlobeNewswire Inc.
Mar 01, 2026 2:45 PM GMT
- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
GlobeNewswire Inc.
Feb 27, 2026 7:45 PM GMT
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patien
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Feb 25, 2026 12:01 PM GMT
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) anno